Multicentre, prospective study on local treatment of metastatic prostate cancer (LoMP study).
#PCSM
#ProstateCancer
cytoreduction
hormone-naïve
metastasis
newly diagnosed
progression-free survival
prostatectomy
prostatic neoplasms
Journal
BJU international
ISSN: 1464-410X
Titre abrégé: BJU Int
Pays: England
ID NLM: 100886721
Informations de publication
Date de publication:
06 2022
06 2022
Historique:
pubmed:
22
7
2021
medline:
1
6
2022
entrez:
21
7
2021
Statut:
ppublish
Résumé
To investigate the role of cytoreductive radical prostatectomy in addition to standard of care for patients with newly diagnosed metastatic prostate cancer. This multicentre, prospective study included asymptomatic patients from 2014 to 2018 (NCT02138721). Cytoreductive radical prostatectomy was offered to all fit patients with resectable tumours, resulting in 40 patients. Standard of care was administered to 40 patients who were ineligible or unwilling to undergo surgery. The primary endpoint was castration resistant cancer-free survival at the time point of ≥50% events. The secondary endpoint was local event-free survival. Kaplan-Meier and Cox regression analyses with propensity-score analysis were applied. After a median (quartiles) follow-up of 35 (24-47) months, 42 patients became castration-resistant or died. The median castration resistant cancer-free survival was 53 (95% confidence interval [CI] 14-92) vs 21 (95% CI 15-27) months for cytoreductive radical prostatectomy compared to standard of care (P = 0.017). The 3-year estimates for local event-free survival were 83% (95% CI 71-95) vs 59% (95% CI 51-67) for cytoreductive radical prostatectomy compared to standard of care (P = 0.012). However, treatment group showed no significance in the multivariable models for castration resistant cancer-free survival (P = 0.5) or local event-free survival (P = 0.3), adjusted for propensity-score analysis. Complications were similar to the non-metastatic setting. Patients undergoing surgery were younger, with lower baseline prostate-specific antigen levels, alkaline phosphatase levels and metastatic burden. The present LoMP study was unable to show a difference between the two inclusion groups regarding castration resistant cancer-free survival for asymptomatic patients with newly diagnosed metastatic prostate cancer. These results validate previous evidence that, in well-selected and informed patients, cytoreductive radical prostatectomy is feasible and safe, with corresponding continence rates compared to the non-metastatic, high-risk setting. Whether cytoreductive radical prostatectomy could be a valuable option to achieve good local palliation needs to be further researched. Overall, the role of cytoreductive radical prostatectomy needs to be further explored in randomized studies to correct for potential bias.
Types de publication
Journal Article
Multicenter Study
Research Support, Non-U.S. Gov't
Langues
eng
Sous-ensembles de citation
IM
Pagination
699-707Informations de copyright
© 2021 The Authors BJU International © 2021 BJU International.
Références
Cornford P, van den Bergh RCN, Briers E et al. EAU-EANM-ESTRO-ESUR-SIOG guidelines on prostate cancer. Part II-2020 update: treatment of relapsing and metastatic prostate cancer. Eur Urol 2021; 79: 263-82
Huggins C. Studies on prostatic cancer. Arch Surg 1941; 43: 209
James ND, Spears MR, Clarke NW et al. Survival with newly diagnosed metastatic prostate cancer in the? docetaxel era?: data from 917 patients in the control arm of the STAMPEDE trial (MRC PR08, CRUK/06/019). Eur Urol 2015; 67: 1028-38
Sweeney CJ, Chen Y-H, Carducci M et al. Chemohormonal therapy in metastatic hormone-sensitive prostate cancer. N Engl J Med 2015; 373: 737-46
James ND, Sydes MR, Clarke NW et al. Addition of docetaxel, zoledronic acid, or both to first-line long-term hormone therapy in prostate cancer (STAMPEDE): survival results from an adaptive, multiarm, multistage, platform randomised controlled trial. Lancet 2016; 387: 1163-77
Fizazi K, Tran NP, Fein L et al. Abiraterone plus prednisone in metastatic, castration-sensitive prostate cancer. N Engl J Med 2017; 377: 352-60
James ND, de Bono JS, Spears MR et al. Abiraterone for prostate cancer not previously treated with hormone therapy. N Engl J Med 2017; 377: 338-51
Kaplan RN, Psaila B, Lyden D. Bone marrow cells in the ‘pre-metastatic niche’: within bone and beyond. Cancer Metastasis Rev 2007; 25: 521-9
Kim M-Y, Oskarsson T, Acharyya S et al. Tumor self-seeding by circulating cancer cells. Cell 2009; 139: 1315-26
Heidenreich A, Pfister D, Porres D. Cytoreductive radical prostatectomy in patients with prostate cancer and low volume skeletal metastases: results of a feasibility and case-control study. J Urol 2015; 193: 832-8
Swanson G, Thompson I, Basler J, Crawford ED. Metastatic prostate cancer-does treatment of the primary tumor matter? J Urol 2006; 176: 1292-8
Parker CC, James ND, Brawley CD et al. Radiotherapy to the primary tumour for newly diagnosed, metastatic prostate cancer (STAMPEDE): a randomised controlled phase 3 trial. Lancet 2018; 392: 2353-66
Carneiro A, Baccaglini W, Glina FPA et al. Impact of local treatment on overall survival of patients with metastatic prostate cancer: systematic review and meta-analysis. Int Braz J Urol 2017; 43: 588-99
Wang Y, Qin Z, Wang Y et al. The role of radical prostatectomy for the treatment of metastatic prostate cancer: a systematic review and meta-analysis. Biosci Rep 2018; 38: BSR20171379
Mottet N, van den Bergh RCN, Briers E et al. EAU-EANM-ESTRO-ESUR-SIOG guidelines on prostate cancer-2020 update. Part 1: screening, diagnosis, and local treatment with curative intent. Eur Urol 2021; 79: 243-62
Epstein JI, Egevad L, Amin MB, Delahunt B, Srigley JR, Humphrey PA. The 2014 International Society of Urological Pathology (ISUP) consensus conference on Gleason grading of prostatic carcinoma. Am J Surg Pathol 2016; 40: 244-52
Cornford P, Bellmunt J, Bolla M et al. EAU-ESTRO-SIOG guidelines on prostate cancer. Part II: treatment of relapsing, metastatic, and castration-resistant prostate cancer. Eur Urol 2017; 71: 630-42
Bettegowda C, Sausen M, Leary RJ et al. Detection of circulating tumor DNA in early- and late-stage human malignancies. Sci Transl Med 2014; 6: 224ra24
Polotti CF, Sterling JA, Kim IY. Cytoreductive prostatectomy in metastatic prostate cancer: current knowledge and future directions. Am J Clin Exp Urol 2019; 7: 80-4
Heidenreich A, Pfister D. Radical cytoreductive prostatectomy in men with prostate cancer and oligometastatic disease. Curr Opin Urol 2020; 30: 90-7
Tilki D, Pompe RS, Bandini M et al. Local treatment for metastatic prostate cancer: a systematic review. Int J Urol 2018; 25: 390-403
Culp SH, Schellhammer PF, Williams MB. Might men diagnosed with metastatic prostate cancer benefit from definitive treatment of the primary tumor? A SEER-based study. Eur Urol 2014; 65: 1058-66
Antwi S, Everson TM. Prognostic impact of definitive local therapy of the primary tumor in men with metastatic prostate cancer at diagnosis: a population-based, propensity score analysis. Cancer Epidemiol 2014; 38: 435-41
Fossati N, Trinh Q-D, Sammon J et al. Identifying optimal candidates for local treatment of the primary tumor among patients diagnosed with metastatic prostate cancer: a SEER-based study. Eur Urol 2015; 67: 3-6
Leyh-Bannurah S-R, Gazdovich S, Budäus L et al. Local therapy improves survival in metastatic prostate cancer. Eur Urol 2017; 72: 118-24
Pompe RS, Karakiewicz PI, Tian Z et al. Oncologic and functional outcomes after radical prostatectomy for high or very high risk prostate cancer: European validation of the current NCCN® guideline. J Urol 2017; 198: 354-61
Satkunasivam R, Kim AE, Desai M et al. Radical prostatectomy or external beam radiation therapy vs no local therapy for survival benefit in metastatic prostate cancer: a SEER-medicare analysis. J Urol 2015; 194: 378-85
Rusthoven CG, Jones BL, Flaig TW et al. Improved survival with prostate radiation in addition to androgen deprivation therapy for men with newly diagnosed metastatic prostate cancer. J Clin Oncol 2016; 34: 2835-42
Löppenberg B, Dalela D, Karabon P et al. The impact of local treatment on overall survival in patients with metastatic prostate cancer on diagnosis: a national cancer data base analysis. Eur Urol 2017; 72: 14-9
Parikh RR, Byun J, Goyal S, Kim IY. Local therapy improves overall survival in patients with newly diagnosed metastatic prostate cancer. Prostate 2017; 77: 559-72
Gratzke C, Engel J, Stief CG. Role of radical prostatectomy in metastatic prostate cancer: data from the Munich cancer registry. Eur Urol 2014; 66: 602-3
Jang WS, Kim MS, Jeong WS et al. Does robot-assisted radical prostatectomy benefit patients with prostate cancer and bone oligometastases? BJU Int 2018; 121: 225-31
Sooriakumaran P, Karnes J, Stief C et al. A multi-institutional analysis of perioperative outcomes in 106 men who underwent radical prostatectomy for distant metastatic prostate cancer at presentation. Eur Urol 2016; 69: 788-94
Heidenreich A, Fossati N, Pfister D et al. Cytoreductive radical prostatectomy in men with prostate cancer and skeletal metastases. Eur Urol Oncol. 2018; 1: 46-53
Gandaglia G, Fossati N, Stabile A et al. Radical prostatectomy in men with oligometastatic prostate cancer: results of a single-institution series with long-term follow-up. Eur Urol 2017; 72: 289-92
Steuber T, Berg KD, Røder MA et al. Does cytoreductive prostatectomy really have an impact on prognosis in prostate cancer patients with low-volume bone metastasis? Results from a prospective case-control study. European Urology Focus 2017; 3: 646-9
Buelens S, Poelaert F, Dhondt B et al. Metastatic burden in newly diagnosed hormone-naive metastatic prostate cancer: comparing definitions of CHAARTED and LATITUDE trial. Urol Oncol Semin Orig Investig 2018; 36: 158.e13-20
Yuh BE, Kwon YS, Shinder BM et al. Results of Phase 1 study on cytoreductive radical prostatectomy in men with newly diagnosed metastatic prostate cancer. Prostate Int 2019; 7: 102-7
Novara G, Ficarra V, Rosen RC et al. Systematic review and meta-analysis of perioperative outcomes and complications after robot-assisted radical prostatectomy. Eur Urol 2012; 62: 431-52
Poelaert F, Verbaeys C, Rappe B et al. Cytoreductive prostatectomy for metastatic prostate cancer: first lessons learned from the multicentric prospective local treatment of metastatic prostate cancer (LoMP) trial. Urology 2017; 106: 146-52
Won AC, Gurney H, Marx G, De Souza P, Patel M. Primary treatment of the prostate improves local palliation in men who ultimately develop castrate-resistant prostate cancer. BJU Int 2013; 112: E250-5